Achieve Life Sciences, Inc. · NASDAQ:ACHV

Achieve Life Sciences — Investor Presentation (2026)

30 slides from Achieve Life Sciences's investor presentation, Nov 18, 2026

  1. Slide 1: Quitting deserves medicine. We're developing it.

    The Quit Company. Quitting deserves medicine. We're developing it. NASDAQ: QUIT

  2. Slide 2: Forward looking statements

    Forward looking statements This presentation contains forward-looking statements, including, but not limited to, statements regarding the timing and nature of cytisinicline clinical development and regulatory review and approval; data results and commercialization strategy and activities; the potent

  3. Slide 3: Cytisinicline

    After two decades without a new medicine to help people quit smoking, we are developing Cytisinicline an investigational compound that binds to nicotinic receptors which demonstrated increased odds of quitting in two randomized trials, including in hard-to-treat patients, and was generally well tole

  4. Slide 4: Driving toward regulatory approval and launch

    Driving toward regulatory approval and launch Anticipated timeline and key milestones Smoking Cessation ORCA-OL 52-week ORCA-OL 52-week safety data4,a efficacy data5,a Potential FDA FDA May 2026 Oct 2026 approval ORCA-2 accepts NDA Q2 2027 Continuing Phase 3 ORCA-3 Phase 3 U.S. manufacturing NDA Fol

  5. Slide 5: Well-capitalized, with an experienced management team

    Well-capitalized, with an experienced management team Upfront Management team3 UP TO $180M $354M Andrew D. Goldberg, MD Milestone- Chief Executive Officer. Physician, healthcare investor (Vivo Capital, Marshall driven warrants Wace), and governance leader; director or observer at 19 life sciences co

  6. Slide 6: A large, underserved U.S. nicotine-dependence market

    A large, underserved U.S. nicotine-dependence market A LARGE POPULATION 1 MOST PLAN TO QUIT. FEW DO ~38M people who smoke and/or vape 67.7% 60.7% 53.3% 8.8% 25M of adults who smoke of adults who vape of adults who smoke of adults who smoke ~18M adults who smoke cigarettes want to quit2 plan to quit3

  7. Slide 7: Nicotine dependence is a costly and growing medical problem

    Nicotine dependence is a costly and growing medical problem SMOKING’S TOLL SMOKING’S TOLL VAPING: A RISING IN LIVES IN DOLLARS PUBLIC HEALTH CRISIS ~1 in 4 ~90% Annual U.S. economic cost: medical care plus lost productivity4 growth in U.S. adult vaping, 2020–20245 $600B of heart disease Smoking (201

  8. Slide 8: Many people who smoke see a specialist, with the highest density in pulmonology and cardiology offices

    Many people who smoke see a specialist, with the highest density in pulmonology and cardiology offices1 WHERE ADULTS WHO SMOKE ARE SEEN 1,2 ADULTS WHO SMOKE SEEN PER CLINICIAN Pulmonology (~18K clinicians) 109 Cardiology (~35K) 84 Primary care (250K+) 60 Psychiatry (~55K) 60 Oncology (~25K) 50 About

  9. Slide 9: 5-fold higher odds of quitting in pooled Phase 3 trials

    INDIVIDUAL STUDIES 12 weeks of cytisinicline showed high odds of PUBLISHED quitting smoking in pooled Phase 3 trials1,2 POOLED PRIMARY ENDPOINT 3 POOLED SECONDARY ENDPOINT 3 Continuous abstinencea, Continuous abstinencec, weeks 9–12 weeks 9–24 Cytisiniclineb Placebo 5-fold OR: 5.3 OR: 5.5 OVER 31.5%

  10. Slide 10: Cytisinicline for smoking cessation: a randomized trial

    Cytisinicline for PUBLISHED smoking cessation: a randomized trial Table 1 from ORCA-21 enrolled hard-to-treat patients1 ᵃ Race and ethnicity were assessed by a participant's response to a fixed- category question. ᵇ Fagerstrom Test for Nicotine Dependence is a 6-item self- administered scale with a

  11. Slide 11: Enrollment criteria and baseline characteristics: ORCA versus varenicline and bupropion Phase 3 trials

    Enrollment criteria and baseline characteristics: ORCA versus the varenicline and bupropion Phase 3 trials Cytisinicline Phase 3 Varenicline (Chantix®) Phase 3 Bupropion SR (Zyban®) Phase 3 ORCA-2; ORCA-31–3 Gonzales 2006; Jorenby 20064,5 Hurt 1997; Jorenby 19996,7 Age Mean 52; no upper limit Mean 4

  12. Slide 12: Higher odds of quitting regardless of number of prior quit attempts

    PRESENTED Cytisinicline showed higher odds of quitting versus placebo regardless of number of prior quit attempts1 5–6-fold NEARLY PRIMARY ENDPOINT Cytisinicline Continuous abstinencea,weeks 9–12 Placebo ≤4 ATTEMPTS OR: 5.9b >4 ATTEMPTS OR: 4.6b p<0.0001c p<0.0001c higher odds of quitting vs 33.8% p

  13. Slide 13: Higher odds of quitting regardless of prior varenicline use

    PRESENTED Cytisinicline showed higher odds of quitting versus placebo regardless of prior varenicline use1 8-fold APPROXIMATELY PRIMARY ENDPOINT Cytisinicline Continuous abstinencea,weeks 9–12 Placebo NO PRIOR USE OF OR: 4.1b PRIOR USE OF VARENICLINE OR: 7.8b VARENICLINE & STILL SMOKING p<0.0001c p<

  14. Slide 14: Potential efficacy in hard-to-treat populations, such as COPD

    PUBLISHED Potential efficacy in hard-to-treat populations, such as people with COPD who smoke1 5-fold PRIMARY ENDPOINT Cytisinicline OVER Continuous abstinencea,weeks 9–12 Placebo NO COPD OR: 5.2b COPD OR: 5.3b p<0.0001c p=0.04c higher odds of quitting vs placebo whether or not 32.6% patients had CO

  15. Slide 15: Cytisinicline in cancer survivors: well tolerated, numerically higher quit rates

    PUBLISHED Cytisinicline in cancer survivors: well tolerated, numerically higher quit rates1 ASCO 2026 Annual Meeting Abstract #e22676, publication only Post hoc analysis of ORCA-2 and ORCA-3 participants with a history of cancer Abstinence at end of treatment Cytisinicline Placebo Participants OR 2.

  16. Slide 16: Quitting smoking after a cancer diagnosis is associated with reduced mortality

    Quitting smoking after a cancer diagnosis, even at an advanced stage, is associated with reduced mortality1 longer survival when risk of death with smoking during 1–2 years people with cancer quit smoking2,3 ~2x radiation therapy in certain cancers4,5 Quit smoking Continued smoking Number at risk Qu

  17. Slide 17: Continuous quitting at the end of treatment and beyond, through week 24

    Continuous quitting at the end of treatment and beyond, through week 24 Odds of sustained quitting over placebo Cytisinicline Pooled Phase 3 Data 1–3 Currently Approved Treatments: Phase 3 Trials 4–6 6 No head-to-head trials of cytisinicline versus approved therapies Varenicline and bupropion odds r

  18. Slide 18: Chemistry, not character

    Chemistry, not character

  19. Slide 19: Cytisinicline was generally well tolerated: under 4% discontinued due to TEAEs

    Cytisinicline was generally well tolerated: under 4% discontinued due to TEAEs1 Data from the ORCA-2 and ORCA-3 Phase 3 trials (safety set, N=1,594); cytisinicline 6- and 12-week arms pooled; values are n (%) Placebo​ Cytisinicline, 6- and 12-week pooled (N=532), n (%) (N=1,062), n (%) At least 1 TE

  20. Slide 20: Tolerability, label warnings, interactions, and duration of current FDA-approved options

    Tolerability, label warnings, interactions, and duration of current FDA-approved options Varenicline Bupropion SR OTC nicotine replacement Chantix® Zyban® Patch, gum, lozenge Tolerability Nausea in up to 30%, and 40% in a 52- Insomnia in up to 40%6 Varies by product7–9 week study1,2 8% discontinued

  21. Slide 21: Minimal 5-HT3 binding may support a favorable tolerability profile

    PUBLISHED Minimal 5-HT3 binding may support a favorable tolerability profile1 Serotonin (5-hydroxytryptamine) 5-HT3 is a receptor commonly associated with nausea and vomiting2 “Cytisinicline selectively targets the α4β2 nicotinic receptor with minimal interaction with the 5-HT3 Receptor binding rece

  22. Slide 22: Matching-adjusted indirect comparison: Cytisinicline vs Varenicline

    PUBLISHED Matching-adjusted indirect comparison: Cytisinicline vs Varenicline PRESENTED MAIC-estimated higher odds of quitting vs varenicline at weeks 9–24; estimated lower odds of nausea vs varenicline A matching-adjusted indirect treatment comparison (MAIC) was conducted to estimate relative effic

  23. Slide 23: Vaping program

    | Ae A\V ae A Vaping A\W/A\V/ program I\ A\W/A\ INT VIN

  24. Slide 24: FDA granted Breakthrough Therapy designation and National Priority Voucher for vaping cessation

    FDA granted cytisinicline Breakthrough Therapy designation and a National Priority Voucher for vaping cessation 2024 2025 Breakthrough Therapy Commissioner’s designation1 National Priority Voucher2 Reserved for therapies showing potential for substantial A new program accelerating review of treatmen

  25. Slide 25: Continuous e-cigarette abstinence (ORCA-V1)

    PUBLISHED Continuous e-cigarette abstinence (%)1 Cytisinicline Placebo Primary Outcome 31.8% End of treatment (Weeks 9–12) 15.1% N=107 N=53 OR 2.64 95% CI 1.06–7.10 p=0.035 1. Rigotti NA, Benowitz NL, Prochaska JJ, et al. Cytisinicline for vaping cessation in adults using nicotine e-cigarettes: the

  26. Slide 26: 52 weeks of continuous therapy

    52 weeks of continuous therapy

  27. Slide 27: 52-week continuous therapy was generally well tolerated with no new safety signals

    PRESENTED 52-week continuous therapy was generally well tolerated with no new safety signals1 Conclusions 1. Rigotti NA, et al. ORCA-OL 52-week safety data. Poster #325, American Thoracic Society (ATS) 2026 International Conference, May 15–20, 2026, Orlando, FL (NCT06435221). Cytisinicline is invest

  28. Slide 28: ORCA-OL: quit rates rose and held to week 52

    PRESENTED ORCA-OL: quit rates rose and held to week 52 CHEST 2026 Annual Meeting Late-breaking abstract, rapid oral presentation Open-label cytisinicline for 52 weeks (N=475): every participant was still smoking and/or vaping after a prior ORCA trial1 4-WEEK CONTINUOUS BIOMARKER VERIFIED ABSTINENCE

  29. Slide 29: Multiple value drivers designed to de-risk potential approval

    Multiple value drivers designed to de-risk potential approval Large, Demonstrated Favorable Defined Resourced underserved efficacy tolerability regulatory for launch market profile path ~38M U.S. adults who Over 5-fold higher odds Minimal 5-HT3 receptor NDA resubmission Up to $354M in smoke, vape, o

  30. Slide 30: Simplicity. Science. Second chances, for good.

    Simplicity. Science. Second chances, for good. NASDAQ: QUIT Contact us at: ir@achieverx.com

Achieve Life Sciences — Investor Presentation (2026) on 6ix